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Abstract
Adaptive designs for clinical trials permit alterations to a study in response to
accumulating data in order to make trials more flexible, ethical and efficient.
These benefits are achieved while preserving the integrity and validity of the trial,
through the pre-specification and proper adjustment for the possible alterations
during the course of the trial. Despite much research in the statistical literature
highlighting the potential advantages of adaptive designs over traditional fixed
designs, the uptake of such methods in clinical research has been slow. One
major reason for this is that different adaptations to trial designs, as well as their
advantages and limitations, remain unfamiliar to large parts of the clinical
community. The aim of this paper is to clarify where adaptive designs can be
used to address specific questions of scientific interest; we introduce the main
features of adaptive designs and commonly used terminology, highlighting their
utility and pitfalls, and illustrate their use through case studies of adaptive trials
ranging from early-phase dose escalation to confirmatory Phase III studies.
Keywords: novel designs; innovative trials; efficient methods; enrichment
designs; multi-arm multi-stage platform trials
1 What are adaptive designs?
In a traditional clinical trial the design is fixed in advance and the study then
carried out as planned with the data being analysed after completion [1] as illus-
trated in Figure 1a. Such a trial design is routine in clinical research, but clearly
inflexible whenever modifications of the planned trial conduct become desirable or
necessary unless a protocol amendment is made. In contrast, adaptive designs pre-
plan possible modifications on the basis of the data accumulating over the course
of the trial. Aspects of a trial that can be modified include: the sample size, the
number of treatment arms, or the allocation ratio to different arms. With these
modifications pre-planned as part of an adaptive design, these changes can be made
without requiring a protocol amendment. Typically these modifications are made
based on data available within the study. It is adaptations of this nature that we
consider here, while we do not consider options such as stopping early due to failure
to meet operational criteria or excessive safety events; although adaptive designs
for some of these do also exist [2]. Adaptations to a trial in progress are made using
pre-planned interim analyses [3]. Figure 1b demonstrates how interim analyses are
a part of the pre-planned design demonstrating the key difference between adaptive
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and fixed (non-adaptive) designs.
(a) Fixed design analysis plan.
(b) Adaptive design analysis plan.
Figure 1: A comparison of fixed and adaptive designs analysis plans.
The defining characteristic of all adaptive designs we discuss in this work is the
use of pre-planned interim analyses to decide if a pre-planned modification of the
ongoing trial should be undertaken, without undermining its integrity and validity
[4]. This is crucial: the integrity of a trial relates to the trial data and a guarantee
that the data have not been used in such a way as to substantially alter the result,
while the validity of the results requires that the study answers the original research
questions appropriately. In an adaptive design, data are looked at more often than in
a traditional study, thus the trial requires further procedures to ensure that data is
collected, analysed, and stored in an appropriate manner at every stage of the trial.
To ensure the validity of an adaptive design, specialised statistical methodology is
required for inference; for example, to provide correct p-values, unbiased estimates,
and confidence intervals for the treatment comparison(s). By their nature adaptive
designs are more complex than their fixed sampling counterparts and this should
be reflected in the reporting [5].
The possibility to make changes during the trial is not a virtue in itself but
rather a gateway to more efficient and ethical trials in comparison to traditional
fixed designs: futile treatment arms may be dropped sooner, more patients may
be randomised to a superior treatment, fewer patients may be required overall,
treatment effects may be estimated with greater precision, a definitive conclusion
may be reached earlier, etc. Adaptive designs can aid in these aspects across all
phases of clinical development [3] (see Table 1 for examples of adaptive designs)
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and therefore lead to more efficient and accurate decision-making throughout the
development process for novel treatments and interventions. Furthermore, seamless
designs make use of adaptive methods that allow for smooth and speedy transitions
between trials of different phases [6–9].
How the adaptation decisions are made is a crucial part of the design of an
adaptive trial. It is often possible to extend beyond classical statistical techniques
and consider the use of a Bayesian methodology in the decision making process.
Bayesian methods allow the incorporation of prior information (such as the current
state of knowledge based on a review of the literature or expert opinion) into the
design and analysis of a trial, provide more intuitive interpretation, and offer many
other benefits [10]. Thus they fit naturally within the setting of adaptive designs.
Adaptive design methodology has been around for more than 25 years [11], with
some methods such as group sequential designs being even older [12]. Despite the
many clear benefits, adaptive designs are still far from established as typical prac-
tice [13–15]. Many reasons for this have been identified [14–17] the main of which
include: lack of expertise and experience (specific to the use of a suitable adaptive
design); lack of software to assist in design and analysis; longer time required for
planning and analysis of the trial; inadequate funding structure to account for un-
certainty about how the trial will run; and the fact that chief investigators may
insist on using a particular method they are comfortable with. We believe that,
besides their knowledge of previous studies in the area or their own past experi-
ence with traditional designs, the main reason why investigators are not inclined to
adopt adaptive designs is a lack of clarity among clinicians and trialists about what
these are and what they can (and cannot) accomplish. Ambiguous terminology with
vague definitions adds to any confusion [18]. To address this ambiguity, we provide
a glossary of the most common types of adaptive design in Table 1.
To help overcome some of the uncertainties and demonstrate when adaptive de-
signs can be useful we focus on four key questions of scientific interest when de-
veloping and testing novel treatments: ‘What is a safe dose?’; ‘Which is the best
treatment among multiple options?’; ‘Which patients will benefit?’; ‘Does the treat-
ment work?’. For each of these questions we shall briefly review several important
adaptive designs, and outline their advantages and disadvantages. We shall illus-
trate methods that can be used from early to late phase clinical development, and
provide real world examples of the designs. Finally, we discuss when the use of an
adaptive design is the best course of action, potentially worthwhile, or not advisable.
2 When to use an adaptive design
We identify four key clinical questions that must be answered when developing a
new treatment across the Phase I, II and III trials (for drug development, termi-
nology differs for surgical or behavioral interventions). We discuss adaptive designs
appropriate to address each of these questions during the clinical development pro-
cess. We shall detail the purpose of each method, outlining both advantages and
disadvantages of their implementation and provide examples of their use in practice.
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2.1 What is a safe dose?
Phase I trials of new drugs are conducted to assess the safety of a treatment, the
aim being to establish the safety profile across a range of available doses. The data
collected are then used to select a dose for further testing in larger Phase II trials, in
which the primary objective is to establish the potential efficacy of the treatment.
In many therapeutic areas, the goal of a Phase I trial is to identify the maximum
tolerated dose (MTD), that is the highest dose that controls the risk of unaccept-
able side effects [19] and hence is deemed safe. In practice, one seeks to identify
the dose at which the probability of a dose-limiting toxicity (DLT) is equal to some
pre-specified target level, usually around 20-33%. In oncology, this is usually done
by treating consenting patients sequentially at increasing doses until too high a
proportion of unacceptable side effects are observed. Several approaches have been
proposed for conducting Phase I dose-escalation studies; we provide a summary of
the most common of these approaches here and show examples of the corresponding
adaptive designs being used in practice.
2.1.1 3+3 design
The most commonly used method for conducting dose-escalation studies is the 3+3
design [20, 21]. It is a simple, rule-based approach under which patients are dosed
in cohorts of three. Based on the number of DLTs observed in the current cohort of
patients, recommendations are made to dose the next three patients at either the
next escalating dose or the current dose. Extending upon the original 3+3 design
a third option of reducing the dose below the current level may be included. Upon
observing excessive toxicity at a dose level (say DLTs in more than 2 in 6 patients),
the trial is terminated and the dose level below is considered to be the MTD. A
simple illustration of this rule is shown in Figure 2. Rule based methods such as
3+3 designs are adaptive, in the sense that the outcomes of the current cohort
determine the dose for the next cohort.
Example: Park et al. [22] performed a Phase I dose-escalating study of docetaxel
in combination with 5-day continuous infusion of 5-fluorouracil (5-FU) in patients
with advanced gastric cancer. The study used a 3+3 design to find the MTD. The
treatment consisted of docetaxel 75 mg/m2 on day 1 in a 1 h infusion followed by
5-FU in continuous infusion from day 1 to day 5, according to the escalating dose
levels. The starting dose of 5-FU was 250 mg/m2/day for 5 days. In the absence
of any DLTs (defined as as febrile neutropenia and/or grade 3/4 toxicity of any
other kind apart from alopecia), dose escalation in additional cohorts continued,
increasing the dose by 250 mg/m2/day for each increment.
Of three patients enrolled on dose level 1 (5-FU 250 mg/m2/day for 5 days), none
experienced DLT. On dose level 2 (5-FU 500mg/m2/day for 5 days), one patient
developed grade 3 stomatitis and fatigue. Three additional patients were enrolled at
this dose level, none of whom experienced any DLT. Thus dose escalation proceeded
to dose level 3 (5-FU 750 mg/m2/day for 5 days). One patient developed grade 3
stomatitis and another patient had febrile neutropenia. Because two of the three
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Figure 2: Decision making in a 3+3 design based on the current cohort.
patients had DLTs dose escalation was stopped at dose level 3. Dose level 2 was
therefore the recommended regimen with docetaxel 75 mg/m2 on day 1 and 5-FU
500 mg/m2/day in a 5-day continuous infusion.
Advantages: The key advantage of the 3+3 design is that it does not require any
time to design. Web applications [23] are available to understand the performance
of such designs. In addition this method is well-known to clinicians, often leading
to its use being well motivated within the trial team.
Disadvantages: The major disadvantages of the 3+3 design will become clear as
we draw comparisons to the methods that follow. In particular we note that the
MTD is not explicitly defined; this means that the most likely dose to be chosen as
the MTD can have a probability of DLT far from the assumed target and can be
highly variable [24–26].
Rule based dose escalation methods such as 3+3 designs are seriously flawed,
which runs afoul of the part of our definition of an adaptive design that demands
integrity and validity. Thus this method being well-known to clinicians, possibly
allowing them to avoid collaboration with a statistician can also present a serious
problem.
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2.1.2 Continual Reassessment Method (CRM)
The Continual Reassessment Method (CRM) [27, 28] uses a simple function to
model the relationship between dose and the risk of a patient experiencing a DLT.
Rather than counting how many people have had DLTs at each dose to determine
whether to dose-escalate or not, all available trial data (and possibly relevant prior
information on the safety profile of the treatment) are used to estimate the prob-
ability of a DLT at each dose level. For a target toxicity level of interest, the dose
for the next patient or cohort is either that with an estimated probability of DLT
closest to the target level, or the highest available dose below the target level. This
process is iterated for each new cohort of patients, as illustrated in Figure 3.
Figure 3: Steps within each iteration of a CRM design.
Example: Paoletti et al. [29] describe the design, conduct and analysis of a multi-
centre Phase I trial to find the MTD (defined as the dose with probability of a DLT
closest to 20%) of rViscumin in patients with solid tumours. A DLT was defined as
any haematological grade 4 or non-haematological grade 3 or grade 4 adverse event
as defined by the National Cancer Institutes Common Terminology Criteria for
Adverse Events (NCI CTCAE) Version 2, with the exclusion of nausea, vomiting,
or rapidly controllable fever. The starting dose of the trial was 10 ng/kg, with fixed
dose levels for further exploration of 20, 40, 100, 200, 400, 800 ng/kg; if no adverse
events of grade 2 or higher were observed after escalation to 800 ng/kg, additional
doses would be added in increments of 800 ng/kg (i.e. 1600, 2400, etc ng/kg).
The design for dose escalation used a two-stage CRM [27]. First, one patient
was assigned to the starting dose of 10 ng/kg and, if adverse events were absent
or grade 1, a new patient was given the next highest dose; if a non-DLT adverse
event of grade 2 or higher was observed, a further two patients would be given the
same dose. Escalation continued in this manner until the first DLT was observed,
at which point the model-based design took over. A one-parameter model [28] was
fitted to the data, and the dose with an estimated probability of DLT closest to 20%
was recommended for the next patient; subject to the constraint that no untested
dose level is skipped. The trial was stopped when the probability of the next five
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patients being given the same dose was at least 90% (i.e. the trial would be unlikely
to gain further information that would affect dose allocation).
The first DLT was observed in the 11th patient who was given 4000 ng/kg; at
which point the CRM part of the design took over. In total 37 patients were re-
cruited the trial before it was terminated under the aforementioned rule, and the
MTD declared as 5600 ng/kg, with an estimated DLT probability of 16%; the es-
timated probability of a DLT at the next highest dose (6400 ng/kg) was 31%. It
is worth noting that the first DLT was recoded during the trial to a non-DLT,
without this a lower MTD would have been selected [29]; this illustrates one of
the benefits of a model-based approach; deviations from the planned course of the
trial are handled without compromising the validity of the design, we can simply
re-estimate our DLT risks at each dose and carry on as normal [30].
One DLT was observed at dose level 4800 ng/kg (patient 26), and two DLTs were
observed at dose level 6400 ng/kg (patients 35 and 37). The description of this trial
by Paoletti et al. [29] is itself a tutorial of the practical considerations for designing
a Phase I trial using the CRM. The authors describe how the statistical work of
the trial helped to inform study clinicians and the Trial Steering Committee, with
whom any final decisions rest. For example, a decision was made to dose another
patient at 3200 ng/kg rather than escalate to 4000 ng/kg as per the design in order
to gather more PK data at this level. Furthermore 10 extremely tolerable (but pre-
sumably inefficacious) dose levels were cleared quickly and with far fewer patients
than the 3+3 design would require.
Advantages: Conceptually, the CRM is a far wiser approach (and more effi-
cient/economic) than the 3+3 design because it uses all available trial data to
make decisions, rather than solely the data from the last cohort [31, 32]. Also,
the CRM targets a pre-specified toxicity level, whereas the 3+3 design provides
an MTD that is not defined explicitly with respect to a risk of a DLT. Numerous
comparative simulation studies have shown the CRM to supersede the 3+3 design
and other competing statistical approaches by dosing more patients in trial at or
near the correct MTD and also by selecting the correct dose as the MTD at the
end of the trial more often [33–37], which in turn can result in higher probability
of success in subsequent Phase II and Phase III clinical trials [38].
Furthermore, the CRM can easily be adapted to include more informative end-
points such as: multiple graded toxicities to incorporate severity of side effects
[39–41]; combinations of safety and efficacy outcomes [42–47]; time-to-event out-
comes to distinguish between toxicity events occurring sooner or later [48, 49]; or
even developed to escalate multiple treatments at once [50–57]. Regulatory author-
ities are also recognising that novel adaptive designs using statistical models are of
great importance, and actively encourage sensible usage of them in Phase I trials
[58, 59].
Disadvantages: The main disadvantage of the CRM design is that more time and
effort is required at the design stage of the trial to assess how it is expected to
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perform. This requires close collaboration between the clinical team and a suitably
trained statistician who is able to guide this optimisation process; although this
opportunity to consider the study more carefully before it begins can only be a
good thing for the study on the whole. The clinical team may still see the CRM as
a “black box”; to resolve this concern, Dose Transition Pathways provide a tool for
visualisation of the CRM escalation/de-escalation decisions [60], which can assist in
the communication of the design. Several computer programs are available (see MD
Anderson Cancer Center software library [61], Vanderbilt University, and packages
within R [62, 63]) for conducting simulation studies, some of which can offer com-
parisons to other popular dose escalation designs including the 3+3 design [63] and
tutorial papers are available offering further guidance [30]. Web based solutions are
on offer for both the CRM and conceptual equivalents [64–66].
2.1.3 Escalation with Overdose Control
The Escalation with Overdose Control (EWOC) approach [67] to Phase I trials
is similar to the CRM in that all patient data in a trial is used to make dose-
escalation decisions and a target toxicity level is used to choose which dose level
the next patient or cohort should receive, with a few key differences. Firstly, rather
than choosing the next patient’s dose as the estimated DLT probability closest to
the target level, the EWOC approach assigns the next patient using a skewed allo-
cation criterion to account for the fact that the overdosing of patients is much more
undesirable compared to the underdosing. This results in a much more conservative
patient allocation approach, with fewer patients being exposed to possible overdos-
ing and experiencing a DLT compared to the CRM, while still benefiting from the
model attempting to allocate the patients near the MTD [68, 69]. Secondly, the
same statistical model is re-expressed in a way that allows focus on the clinically
relevant parameters, the MTD, and the probability of a DLT at the lowest dose.
This means that prior information about the treatment being investigated can eas-
ily be incorporated and one can visualise how the distribution of the MTD changes
over the course of the trial.
Example: Nishio et al. [70] conducted a Phase I dose-escalation study of ceritinib
in patients with advanced anaplastic lymphoma kinase-rearranged, non-small-cell
lung cancer or other tumours. A Bayesian EWOC approach was used to govern
dose-escalation, allocating the next patient to the largest dose with an estimated
probability of less than 25% that the risk of a DLT exceeds 33%. In total, 19 pa-
tients were recruited to the trial: three patients received doses of 300 mg, 6 patients
received doses of 450 mg, four patients received doses of 600 mg and six patients
received doses of 750 mg. Two patients experienced DLTs, one at 600 mg and the
other at 750 mg. At the end of the trial, the MTD was chosen as 750 mg; the largest
dose at which the estimated probability of the risk of a DLT exceeding 33% was
less than the target 25% (the probability was 7.3% for the chosen dose). Although
the aim of the trial was not to evaluate efficacy of ceritinib in this population, 10
patients achieved partial responses to their cancers.
Advantages: The EWOC approach offers a more cautious dose-escalation design
that reduces the chance of patients being treated at excessively toxic doses [67].
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However, a slower dose-escalation approach may increase the number of patients
treated at sub-therapeutic doses; although this also means that fewer patients are
treated at doses close to the MTD. Similar to the CRM, the EWOC approach
has also been adapted to be used in trials with more complex outcomes, such as
time-to-event data [71], and for combinations of treatments [72, 73]. Furthermore,
the escalation control threshold can be altered depending on the trial context, and
may change during the conduct of the trial [68, 69]; this offers a conservative dose-
escalation schema at the start of the trial when there is little data available, but
as more data are accrued, dose-escalation gradually becomes less conservative, and
the MTD can be targeted more quickly than with the standard EWOC approach
[68, 69, 74].
Disadvantages: Similar to implementation of the CRM, care is required when de-
signing trials using the EWOC approach. For example, choice of the MTD estimator
needs to be considered; several trials use the same criterion as that by Nishio et
al. [70], i.e. the MTD is the dose that would be given to a new patient had they
entered a trial, whereas others have used the posterior median of the MTD distri-
bution. The implications of each choice need to be considered well in advance [75].
Furthermore, if the investigators plan to relax the escalation control mechanism
(that is, decrease how cautious escalation is as the trial continues), as has been
done in practice before [69, 76, 77], the implications of this decision need to be
considered. The EWOC approach may recommend to escalate the dose even when
the most recently evaluated patient experienced a DLT [78].
2.1.4 Summary
Despite the 3+3 designs frequent use in Phase I clinical trials over the last 30 years
[13, 79–81], there is overwhelming consensus among statisticians and methodolo-
gists that it is sub-optimal, and more efficient designs for identifying the MTD
should be used [38, 82, 83]. Many alternative designs propose the use of statistical
models, such as the two alternatives we have presented here; both of which have
superior operating characteristics over the 3+3 design.
The two model-based approaches discussed above serve as the main frameworks
for other proposed model-based approaches, which are designed for trials with novel
drug combinations, endpoints that use time-to-event data and/or efficacy outcomes,
or information about the severity of observed toxicities. These designs have slowly
found their way into clinical practice in recent years, primarily in oncology for
cytotoxic treatments. However, these approaches can be used for novel molecu-
larly targeted anti-cancer therapies [84], and in other disease areas altogether:
OQuigley et al. [85] proposed CRM-type designs for use in dose-finding studies
for anti-retroviral drugs to treat Human Immunodeficiency Virus (HIV); Lu et al.
[86] conducted a dose-escalation study of quercetin in patients with Hepatitis C;
Whitehead et al. [87] proposed a model-based design for trials in healthy volunteers;
and Lyden et al.[88] used a CRM design in the RHAPSODY trial in stroke patients.
Whilst there is no one size fits all approach for conducting adaptive dose-escalation
studies, there is overwhelming evidence that model-based designs are far better than
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the standard rule-based designs, such as the 3+3 design. Model-based designs are
on the whole more efficient in their use of data, less likely to dose patients at sub-
therapeutic doses, more likely to recommend the correct MTD at the end of the
trial, and provide an MTD estimate that directly relates to a specified target level
of toxicity. We have discussed two approaches here for brevity, though many other
alternatives have also been proposed, including designs based on optimal design
theory [89–92] and model-free designs [93–96], without the shortcomings of com-
mon rule-based designs like 3+3. The increasing usage of model-based designs in
practice, as well as their acknowledgement in regulatory guidance and the provision
of guideline documents [97], formal courses and computer software is indicative of
the changing tide of clinical practice for Phase I trials.
2.2 Which is the best treatment among multiple options?
After establishing the safety of a treatment the next question is naturally “how
does it perform?”. In this section, we consider randomised clinical trials that aim to
select the best treatment arm among multiple experimental treatment arms (where
these can be different treatments, doses of the same treatment or combinations
of these two options). The methods we explore are typically considered for use in
Phase II of the development process, where we wish to select a treatment or dose
for further study. A common theme is to compare multiple arms against a common
control. We explore methods that seek to remove less beneficial treatments from the
trial quickly, giving patients a better chance of receiving an efficacious treatment. In
addition model-based approaches allow modelling of the dose-response relationship
in order to provide a deeper understanding of this in an efficient way. This is useful
in trials where the different arms correspond to a series of exposure levels (such as
doses of a drug, duration or intensity of radiotherapy, or number of therapy sessions).
2.2.1 Multi-Arm Multi-Stage (MAMS)
Multi-Arm Multi-Stage (MAMS) [98] trials allow the simultaneous testing of multi-
ple experimental treatment arms with a single common control. They are conducted
over multiple stages to allow for the early stopping of recruitment for either efficacy
or futility. For example, if an experimental treatment is found to be performing
poorly it may be dropped for futility at a pre-planned interim analysis (if all exper-
imental arms are dropped, the trial is stopped for futility). Alternatively, the trial
may end early when a treatment is shown to be sufficiently efficacious. We cover
group sequential designs in more detail in Section 2.4.1 but MAMS designs apply
similar methodology while comparing multiple experimental treatments simultane-
ously. A simplex schematic of how a two-stage four-arm trial using MAMS design
can progress is given in Figure 4.
MAMS trials are often designed using a pre-planned set of adaptation rules to
find the best treatment to carry forward for further study [99] or carry forward
all promising treatments [100]. Alternatively more flexible testing methods [101–
103] allow methodological freedom as to how adaptation decisions are made. Open
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Figure 4: A two-stage four-arm MAMS design
source software is available to assist in the design and analysis of MAMS trials in
the form of the “MAMS” package for R [104]. Alternatively in STATA there are
several modules available such as “nStage” [105], “nStagebin” [106], and “DESMA”
[107].
Example: The TAILoR trial [108] was a Phase II, multicentre, randomised, open-
labelled, dose-ranging trial of telmisartan using a two-stage MAMS design. The trial
planned recruitment of up to 336 HIV-positive individuals over a 48-week period,
with a single interim analysis planned after 168 patients had completed 24 weeks on
either an intervention or control treatment. Patients were randomised with equal
probability to one of four groups: no treatment (control), 20mg telmisartan daily,
40mg telmisartan daily, or 80mg telmisartan daily.
At the interim analysis there were three possible outcomes based on assessment of
change in HOMA-IR index from baseline to 24 weeks: if one telmisartan dose was
substantially more effective than control, the study would stop and that dose would
be recommended for further study; if all telmisartan doses were less effective than
control, the study would stop with no dose recommended for further study; if one
or more doses were better than control but none met the first criterion, the study
would continue and patients would have been randomised between these remaining
dose(s) and control. If the trial entered the second stage then a final analysis would
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be conducted with two possible outcomes based on the primary endpoint: either
the best dose is significantly more effective than the control in which case it is
recommended for further study; or no dose is significantly better than control in
which case no dose is recommended.
A total of 377 patients were recruited [109] (note this difference in sample size
was due to higher than expected drop-out). In stage one, 48, 49, 47, and 45 pa-
tients were randomised to control and 20, 40, and 80 mg telmisartan, respectively.
Following the interim analysis only 80 mg telmisartan was taken forward into stage
two. At the end of stage two 105 patients had been recruited to control and 106
to the 80-mg arm (in total), there was no difference in HOMA-IR (estimated ef-
fect, 0.007; SE, 0.106) at 24 weeks between the telmisartan (80 mg) and control arm.
Advantages: MAMS designs are useful when there are multiple promising treat-
ments and there is no strong belief that one treatment will be more beneficial
compared to the others. The use of a shared control group considerably reduces
the number of patients that need to be recruited compared to separate RCTs test-
ing each treatment. Other advantages are: treatments that provide no benefit to
patients are dropped from the trial leading to a potentially smaller sample size;
patients have a higher chance of receiving an experimental treatment compared to
a 2-arm trial, which may improve recruitment to the study [110, 111]; they require
less administrative and logistical effort than setting up separate trials and thus can
substantially speed up the development process [112].
Disadvantages: MAMS trials require an outcome measure that allows a timely
decision about the worth of each treatment. Consequently either the primary end-
point needs to be relatively quickly observed (in comparison to patient accrual) or
an intermediate measure that is strongly associated with the primary endpoint is
required for interim decision making. MAMS designs will generally require a larger
potential maximum sample size than a corresponding multi-arm fixed design (al-
though still smaller than several separate trials due to the use of a common control
arm). The MAMS approach has a variable sample size depending on which decisions
are made through the trial, which will make planning more cumbersome, although
the possible pathways are pre-defined; this is more variable than is typical of even
other adaptive designs because decisions relate to each treatment individually.
2.2.2 Drop The Loser (DTL)
Drop The Loser (DTL) designs [113, 114] are closely related to MAMS designs [115]
in that they aim to compare several experimental treatments to a common control
over multiple stages. The key difference between the two methods is that in a DTL
design it is pre-determined how many arms will be dropped after each stage of
the trial. As the name suggests the worst performing experimental treatments are
dropped at interim analysis, leaving only one treatment to compare to control at
the final analysis.
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Example: The ELEFANT trial [116] is a randomised controlled, multicentre, three-
armed trial testing the concept that early elimination of triglycerides and toxic free
fatty acids from the blood is beneficial in HyperTriGlyceridemia-induced Acute
Pancreatitis (HTG-AP). This study will be conducted using a two-stage DTL de-
sign, dropping the inferior experimental treatment arm at the interim analysis.
Patients with HTG-AP are randomised with equal probability into three groups:
patients who undergo plasmapheresis and receive aggressive fluid resuscitation; pa-
tients who receive insulin and heparin treatment with aggressive fluid resuscitation;
and patients with aggressive fluid resuscitation only (the control). The target sam-
ple size is 495 in order to detect a 66% relative risk reduction, using a 10% dropout
rate with 80% power at 5% significance level. The the study began in February
2019 and is expected to finish December 2024.
Advantages: As with MAMS designs the key advantage is that the use of the
shared control group considerably reduces the number of patients required. Of fur-
ther practical benefit is that there is a guarantee that a pre-specified number of
arms will be dropped during the course of the trial, meaning that the required
sample size is known before commencement of the trial [115]. At the conclusion
of the trial only one experimental treatment remains to be compared against the
control making for a clear interpretation of results.
Disadvantages: The choice to only continue the most efficacious treatments may
not always be the best choice; consider for example an interim analysis where a
dropped treatment has demonstrated an almost equivalent positive effect to a treat-
ment that continues in the trial, it is possible that a suitable treatment has been
dropped by chance. In addition a similar operational complexity to MAMS designs
is observed here as it is unknown which treatments will be carried through the trial
(although as noted previously the exact required sample size is known which it is
not for a MAMS design).
2.2.3 Response-Adaptive Randomisation (RAR)
At the beginning of the trial, usually not much is known about the efficacy of the
experimental treatment arms; hence, equal randomisation is often sensible under a
clinical equipoise principle. However, as data accumulates it becomes challenging
from an ethical standpoint to randomise patients to a treatment arm that accumu-
lating trial data suggest may be inferior, especially when the disease under study is
rare or life-threatening. One way to resolve this dilemma is to align the randomisa-
tion probabilities with the observed efficacy of the different arms, which is exactly
what Response-Adaptive Randomisation (RAR) does (Figure 5).
The idea of RAR dates back to 1933 [117] and since then several methods to align
randomisation probabilities and observed evidence of efficacy have been proposed
in the specialised literature [118, 119]. Thompson [117] proposed to randomise pa-
tients to arms with a probability that is proportional to the probability of an arm
being the best arm. Regardless of how these probabilities are defined and applied
for a specific adaptation rule, they can be also used to define further adaptations to
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Figure 5: A description of a RAR procedure.
the trial depending on the values they assume. For example, if the allocation prob-
ability goes below or rises above a certain value, arms can be dropped for futility
or selected in a similar way to a MAMS study [120, 121]. Free software is available
from the MD Anderson website [61]. The R package “bandit” offers an alternative
to the implementation of such designs [122].
Example: A prospective, randomised study reported by Giles et al. [123] was
conducted in patients aged 50 years or older with untreated, adverse karyotype,
acute myeloid leukemia to assess three troxacitabine-based regimes: idarubicin and
cytarabine (the control arm); troxacitabine and cytarabine; and troxacitabine and
idarubicin. The trial used a Bayesian RAR design along the lines proposed by
Thompson [117]. Thirty-four patients were recruited and randomised to one of the
three arms. Initially an equal chance for randomisation to each arm was ensured,
but treatment arms with a higher success rate, defined as the proportion of patients
having complete remission within 49 days of starting treatment, would receive a
greater proportion of patients. The randomisation probabilities were updated after
every patient. The design would drop arms if their assignment probabilities became
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too low or promote them to Phase III if their assignment probability was high
enough. The probability of a patient being randomised to the control arm was fixed
until the first experimental arm was dropped. This occurred when the randomisa-
tion probability for the dropped experimental arm was 0.072 [124].
Of the thirty-four patients recruited 18 were randomised to idarubicin and cytara-
bine, randomisation to troxacitabine and idarubicin stopped after five patients and
randomisation to troxacitabine and cytarabine stopped after 11 patients. Success
rates were 55% (10 of 18 patients) with idarubicin and cytarabine, 27% (three of
11 patients) with troxacitabine and cytarabine, and 0% (zero of five patients) with
troxacitabine and idarubicin, while survival was comparable with all three regimens.
Advantages: RAR can increase the overall proportion of patients enrolled in the
trial who benefit from the treatment they receive while controlling type I (the prob-
ability of falsely rejecting the null hypothesis when it is true, a false positive) and
type II error rates (the probability of failing to reject the null hypothesis when it
is false, a false negative) [125–127]. This mitigates potential ethical conflicts [128]
that can arise during a trial when equipoise is broken by accumulating evidence
and makes the trial more appealing to patients [111]. Therefore, the RAR design
may improve the recruitment rates [129]. The main motivation for RAR designs
is to ensure that more trial participants receive the best treatments, it is possible
to use such response adaptive methods to optimise other characteristics (such as
power) of the trial [130]. In a multi-armed context RAR can shorten the time of
development and more efficiently identify responding patient populations [131].
Disadvantages: RAR designs have been criticized for a number of reasons [132]
although many of the raised concerns can be addressed. Logistics of trial conduct is
a noticeable obstacle in RAR due to the constantly changing randomisation [133];
requiring more complex randomisation systems which in turn may impact things
such as drug supply and manufacture. When the main advantage pursued is patient
benefit, this may compromise other characteristics of the design; for example in a
two-arm trial RAR designs will require larger sample sizes than a traditional fixed
design with equal sample sizes in both arms; methods to account for such compro-
mise have been proposed [125, 134].
Choosing an approach from the existing variants of RAR can be challenging;
in most cases, balancing the need for maximising statistical power and randomly
assigning patients in an ethical manner is required. Most RAR methods require the
availability of a reliable short-term outcome (although the exact form of the data
may vary [125, 135]); however, most of them can result in bias; therefore requiring
the use of extra correction methods if collected data is used for estimation purposes
[136]. Another statistical concern is control of the type I and type II error rates.
As discussed above this is possible but requires intensive simulations or the use of
specific theoretical results [119, 130, 131, 137]; this creates an additional burden at
the design stage, requiring additional time and support.
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2.2.4 MCP-Mod
The adaptive designs described in this section so far make no assumption about the
relationship between the treatment arms, i.e. it is not required that one can order
the arms with respect to the increasing efficacy.
In Phase II dose-ranging studies, patients are typically randomised to either one
of a number of doses and possibly a placebo. The objective of the trial is to find
which dose (if any) should be tested in Phase III. The target dose is often the min-
imum effective dose, the smallest dose giving a particular clinically relevant effect.
A traditional approach to find the target dose is based on pairwise comparisons.
This approach, however, uses the information from the corresponding doses only and
typically results in larger sample sizes required in the trial [138]. As an alternative
MCP-Mod [139, 140] employs a dose-response model and allows for interpolation
between the doses.
MCP-Mod is a two-stage method that combines Multiple Comparison Procedures
(of dose levels) and MODeling approaches. At the planning stage, the set of possible
models for the relationship between dose and response are defined, such as those
shown in Figure 6. The inclusion of several models addresses the issue of some
of the models being potentially mis-specified. At the trial stage, the MCP step
checks whether there is any dose-response signal. This is done through hypothesis
tests for each model while adjusting for the fact that there are multiple candidate
models. This ensures control of the probability of making incorrect claims of a
dose-response signal (a type I error). If no models are found to be significant, it is
concluded that the dose-response signal cannot be detected given the observed data.
Figure 6: Model fitting in MCP-Mod.
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Once the dose-response signal is established, a single model is selected, or if mul-
tiple models are selected, an average over these models is made. The selection of
models can be based either on tests performed at the MCP step or on some other
measures such as the Akaike Information Criterion [141] (a measure of fit of statis-
tical models). The selected model is then used to determine the dose to be tested in
the subsequent trial. We refer the reader to the works focusing on the step-by-step
application of MCP-Mod in practice [138, 142].
Example: Verrier et al. [143] described the application of MCP-Mod in a placebo
controlled parallel group study undertaken in hypercholesterolaemic patients, which
evaluated the change in low-density lipoprotein cholesterol (LDLC, mg/dL) follow-
ing 12-weeks treatment as the primary endpoint. Three active doses were studied:
50, 100, and 150 mg, and nearly 30 patients per treatment group were recruited.
The objective of the trial was two-fold: (i) to demonstrate the dose-effect of the
compound, and (ii) to select the dose providing at least a 50% decrease in LDLC.
The set of pre-specified candidate models was composed of linear, logistic (four
possible pairs of parameters obtained from the guess that 50% of the maximum
effect occured at 50, 75, 100, or 125 mg, respectively, defined four possible models),
and quadratic (corresponding to the maximum effect at 125 mg) models. The model
selected by the hypothesis tests was a logistic model and the estimated target dose
was 76.7 mg. Alternatively using an information criterion approach the selected
model was the quadratic model and the estimated target dose was 78.2 mg. To
check the robustness of the results, model-averaging was also used and resulted in
nearly the same estimated target dose. This analysis informed the selection of the
dose for Phase III trials for which the dose of 75 mg was chosen. This choice of dose
was not one of those three active doses directly studied but could be selected due
to using a model-based approach.
Advantages: MCP-Mod allows for a more efficient use of data. Since its proposal,
MCP-Mod was thoroughly studied, and many practical recommendations are avail-
able [138]. MCP-Mod has been successfully applied in a number of trials [144] as
primary or secondary analysis, and the European Medicines Agency issued a qual-
ification opinion of MCP-Mod [145] concluding that MCP-Mod uses available data
better than the traditional pairwise comparisons; and the FDA also designated the
method as fit for purpose [146]. There is software that implements the methodology,
e.g. an R-package, DoseFinding [147] and PROC MCPMOD in SAS.
Disadvantages: The method can be sensitive to the model assumptions, specifi-
cally, to the initial guess of the model parameters [148]. This can result in signifi-
cantly lower power if the dose response relationship is not well approximated by one
of the pre-specified candidate models. The number of doses to be included should
inform the choice of the candidate models. Finally, the application of MCP-Mod
should be approached with much care or avoided at all when the treatment regimens
consist of various drugs, schedules and doses.
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2.2.5 Summary
The methods presented in this section are suitable for selecting a treatment or dose
for further study or, if constructed correctly, even allow for formal testing in a
confirmatory setting. With RAR we see the goal of focusing on the more effective
treatments while studying several was thought of as an important topic almost 90
years ago; however, it is only in the last 30 years or so that this topic has gained
traction as a more active area of methodological research. These more modern
methods will need to be sufficiently well understood before we start to see their use
in clinical practice [149].
Each of the methods discussed use adaptation rules to make efficient comparisons
of several treatments or doses, filling a niche of application. There is a common
advantage of reducing the number of patients (or expected number of patients) re-
quired to achieve the same strength of evidence when compared with fixed sampling
alternatives. The key challenge is making informed decisions given the uncertainty
about how the trial will develop before patient information is observed, whether
that be how many patients will be required overall or how many patients will be
allocated to each treatment.
For RAR, MAMS and DTL designs the trial is able to focus on those treatments
that are demonstrating effectiveness. For trial participants and from an ethical per-
spective these methods are appealing as they increase the chance of receiving a
treatment that is more likely to be effective. Further to this the model-based ap-
proach of MCP-Mod increases understanding of the relationship between dose and
response in order to better allocate patients based on current trial data, which in
turn allows greater confidence about the choice of dose for further study.
2.3 Which patients will benefit?
Late into the development cycle, for example in Phase III of drug development,
we wish to confirm the treatment works by demonstrating efficacy. An important
aspect of this is to ensure the right patients receive the treatment (i.e. those who
will gain a meaningful benefit from the treatment). Here, we focus on randomised
clinical trials that use clinically relevant biomarkers to identify patients who may
be sensitive to a treatment and therefore likely to respond. This is usually the case
when several new therapies and corresponding predictive biomarkers are available
for testing within a disease setting.
2.3.1 Covariate-Adjusted Response Adaptive (CARA)
A form of RAR (see Section 2.2.3) that may be useful for trials in the context of
population selection is Covariate Adjusted Response Adaptive (CARA) where ran-
domisation probabilities are aligned to not only the observed efficacy of arms but
also the patient’s observed biomarker information. CARA skews allocation probabil-
ities towards the best performing arms according to a patient’s set of characteristics.
Such changes in randomisation probabilities based upon available biomarker infor-
mation are one of the most common adaptations in biomarker adaptive designs [150].
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CARA procedures are sometimes (incorrectly) referred to as minimisation proce-
dures or dynamic allocation; some of the methods referred to with these names are
essentially very different in their goals and nature. For example, some CARA proce-
dures have been proposed altering the randomisation (similar to RAR) [151] while
other methods do not do so in a randomised fashion determining allocation proba-
bilities based solely on covariates [152–154]. Some CARA procedures are designed
to minimise imbalances on important covariates only [151, 152] (rather than giving
the best treatment for a given patient) while other methods have an efficiency goal,
being designed to minimise the variance of the treatment effect in the presence of
covariates (i.e. to maximise statistical power) [155]. Finally, some CARA rules will
aim to assign the largest number of patients to the best treatment while accounting
for patients differences in biomarkers (as long as they are relevant to determining
their best treatment) [156].
Example: The BATTLE [157] trial is an example of a prospective, biopsy-
mandated, biomarker-based, adaptively randomised [158] study conducted in 255
pre-treated lung cancer patients. Following an initial equal randomisation period
for the first 97 patients, 158 patients were adaptively randomised to four arms: er-
lotinib, vandetanib, erlotinib plus bexarotene, or sorafenib, based on relevant molec-
ular biomarkers. The allocation probabilities were adapted based on the observed
signal of interaction between the arms and biomarkers using a CARA procedure.
Results include a 46% 8-week disease control rate (primary endpoint) and evidence
of an impressive benefit from sorafenib among mutant-KRAS patients.
Advantages/Disadvantages: Because they fall within the RAR procedures, advan-
tages and disadvantages of CARA designs are almost the same as with RAR. The
main advantage of incorporating CARA rules into biomarker clinical trials is that
they allow the flexibility of introducing balance, efficiency or ethical goals according
to what might be more relevant for a particular trial.
2.3.2 Population Enrichment
Population Enrichment designs are useful when two or more biomarker-defined
subgroups are known before the trial commences. With uncertainty about which
populations should be recruited for the trial they ensure patients are recruited from
appropriate populations using interim analyses to select which sub-populations to
recruit from for the remainder of the trial. Figure 7 shows an example of how an
adaptive enrichment design can progress. In a non-adaptive trial in the equivalent
setting, the study team must make this sub-population selection before the trial
begins without the benefit of trial observations. Population Enrichment designs
are typically planned with one of two goals in mind: target the sub-population
where patients receive the greatest benefit; or alternatively stop recruiting from
sub-populations where the treatment may not provide a benefit.
Fully flexible hypothesis testing methods [102, 103, 159] may be constructed to
preserve the statistical integrity of the trial while allowing freedom in the way de-
cisions are made about sub-populations. The decision making methodology is a
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Figure 7: An adaptive enrichment design examining 2 subgroups.
key design element in an adaptive population enrichment trial to which there are
several approaches, both Bayesian [160–162] and classical techniques such as setting
thresholds for the observed effects being applied [163, 164].
Example: TAPPAS [165, 166] is a trial of TRC105 (an antibody) and pazopanib
versus pazopanib alone in patients with advanced angiosarcoma. The study identi-
fied two sub-groups, those with cutaneous advanced angiosarcoma and those with
non-cutaneous advanced angiosarcoma. Since there was some indication of greater
tumour sensitivity to TRC105 in the cutaneous sub-group an adaptive enrichment
design was used with the option to restrict enrolment to the cutaneous subgroup
based on a interim analysis. The primary endpoint for this study was progression
free survival, with an initial sample size of 124 patients to be followed until 95
events (progression or death) have been observed.
At the interim analysis the data monitoring committee were able to recommend
one of three pre-planned actions: continue as planned with the full population (re-
cruiting 124 patients followed until 95 events in total); continue with the full popu-
lation and an increase in sample size and progression free survival events (recruiting
200 patients followed until 170 events in total); continue with only the cutaneous
subgroup, thereby enriching the study population (recruiting 170 patients followed
until 110 events in total).
The study concluded having recruited a total of 128 patients (close to the tar-
geted recruitment of 124 with the trial continuing as planned in the full population),
with 64 patients randomised to each the experimental treatment and the control.
It was concluded that TRC105did not demonstrate activity when combined with
pazopanib.
Advantages: Population enrichment designs recruit fewer patients from subgroups
that do not benefit from the treatment allowing the trial to focus on those patients
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who are receiving a worthwhile benefit. In scenarios where there is uncertainty about
which subgroups benefit from the new treatment, the adaptive method can offer an
improvement over non-adaptive alternatives. This is because it is able to offer the
benefit of increasing the sample size if one subgroup is preferable without sacrificing
the opportunity to test the new treatment in all patients before the observation of
any patients. In addition, population enrichment offers a compromise between the
possible fixed designs (for example recruiting only from one of the two sub-groups,
or the full population). This compromise can be appealing in cases where there is
disagreement between which (sub-)population(s) should be recruited from.
Disadvantages: Computing decision rules that will provide good overall trial per-
formance is often non-trivial [161], increasing the workload in setting up the trial.
Similarly, evaluating the expected performance of the trial is a non-trivial exercise,
typically requiring some form of simulation. Possible changes to eligibility criteria
after the interim analysis make planning patient recruitment challenging.
2.3.3 Summary
In this section we have discussed designs suitable for phase II and phase III of
clinical development with the aim to test the effectiveness of a biomarker guided
approach to treatment. This is well aligned with the shift across healthcare towards
personalised medicine, ensuring patients receive treatments appropriate to them.
Despite active research in this area, these methods appear to have the lowest uptake
at the time of writing, although with the drive towards personalised healthcare they
are likely to become increasingly relevant.
The suitability of each design depends on whether predictive biomarkers have
been defined or are yet to be fully developed and tested. The methods presented
allow formal testing for efficacy of an experimental treatment in biomarker defined
sub-populations. Of note for methods that assume there is a pre-defined biomarker,
the methods assume these biomarker groups are well defined, with little work on
how to properly account for this should this assumption be violated [167]. Beyond
being structured to allow formal analysis of sub-groups there is also a large ethical
benefit to these designs; exposing as few patients as possible to treatments from
which they may not receive a benefit.
Should no such pre-defined biomarkers be available one might consider adap-
tive signature designs [168, 169], also referred to as biomarker adaptive designs
[150, 170, 171]. They aim to identify and use predictive biomarkers [170] during
the trial. They help to improve the chances of identifying patients who will ben-
efit from the treatment, whilst still providing accurate treatment effect estimates;
this is done while maximising the use of the data used in the construction of the
biomaker itself. However, the identification of predictive biomarkers in itself is not
a trivial task and adds a large amount of complexity when working in the setting
of a confirmatory clinical trial. With the sub-groups undefined, this creates further
uncertainty adding a large administrative burden to implementing such a design.
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An extension beyond the methods presented is the wider scope of umbrella [172]
and basket trials [173], which make use of more detailed biomarker information.
Broadly speaking: a basket trial examines a single experimental treatment in mul-
tiple sub-types of a single biomarker, while an umbrella trial may consider mutiple
biomarkers each of which may require a different treatment.
2.4 Does the treatment work?
In this section, we consider treatments late in the development cycle, typically
phase III (although viable in phase II also), where we wish to show conclusively
that a novel treatment is an improvement over the current standard of care. A
conventional aim at this stage of development is to be efficient, both in terms of
the time that is required to conduct the trial and the number of patients we must
recruit; the methods that follow attempt to make the trial more efficient while also
ensuring that the overall probability of a successful outcome is maintained or in-
creased. Methods aiming to be efficient in recruiting the correct number of patients
have both an operational and ethical benefit; ensuring patients are not subject to
an experimental treatment for a trial that is underpowered (i.e. has a low chance
of detecting a meaningful effect) or when their contribution to the overall result is
not required.
2.4.1 Group sequential designs
Group sequential designs are the most widespread [174] of the adaptive designs
we consider in this paper. A group sequential trial differs from a more traditional
phase III clinical trial in that one or more pre-planned interim analyses may be
used to assess efficacy; if there is strong evidence the experimental treatment is
superior to control, or indeed that both have the same effect, then the trial may be
terminated early as depicted in Figure 8. Investigators must decide before the trial
whether binding or non-binding futility boundaries are to be used, that is whether
the early stopping for futility must be strictly adhered to, or whether they can be
overruled without risking an inflation of the type I error rate. This choice affects
on the overall definition of the early stopping thresholds (both for superiority and
for futility).
To enable early stopping of the trial while maintaining control of the type I error
rate as required in a confirmatory setting, group sequential trials use pre-defined
stopping rules. At each interim analysis the current data for the experimental and
control arms are compared to construct a test statistic. If the test statistic is suffi-
ciently high/low the trial is stopped early for efficacy/lack of a demonstrated benefit
of the treatment; if neither criterion is met, the trial continues to the next interim
or final analysis.
Several approaches to the definition of stopping rules for group sequential designs
have been proposed [12, 175–177]. Jennison & Turnbull [178] provide a comprehen-
sive guide to group sequential designs and their application. Whitehead (2011) [179]
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Figure 8: Demonstration of stopping boundaries in a 2 stage group-sequential design.
describes the implementation of group sequential methods using SAS, in addition
the gsDesign [180] and optGS [181] packages in R are open source alternatives al-
lowing the construction and analysis of group sequential designs.
Example: The INTERCEPT trial [182, 183] was a randomised, double blind trial
in patients with acute myocardial infarction. The trial used a group sequential de-
sign to achieve 80% power to detect a 33% between-group difference in cumulative
first event rate of cardiac death, non-fatal reinfarction, or refractory ischaemia. In-
terim analyses were conducted after enrolment of 300 patients, and at intervals of
roughly 300 patients thereafter. The stopping boundaries were constructed using a
double triangular test [177].
Recruitment was stopped after the third interim analysis. In total the trial re-
cruited 874 patients with acute myocardial infarction, but without congestive heart
failure, who first received thrombolytic agents. 430 patients were randomised to 300
mg oral diltiazem once daily, and 444 patients were randomised to placebo initiated
within 3696 hours of infarct onset, and given for up to 6 months. It was concluded
that the pre-specified 33% between-group difference for the primary endpoint would
probably not be achieved.
Advantages: Group sequential designs offer a reduction in the expected sample
size of the trial compared to a traditional trial design with a fixed sample size. This
is because there is a high probability that the trial will stop early due to strong
evidence that the treatment either is or is not effective. The reduction in expected
sample size compared to a fixed design, is typically around 15% for O’Brien-Fleming
[175] boundaries [184]. Group sequential designs are the optimal choice in terms of
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minimising the expected sample size [178]. The implication is that any other design
aiming to reduce the expected sample size can only perform as well as, but never
better than, the group sequential option. In addition, with group sequential meth-
ods being widespread [174] their implementation is likely to be simpler than more
novel adaptive designs, and also more familiar to regulators and ethics committees.
Disadvantages: Taking multiple looks at the data to provide the opportunity for
early stopping requires careful definition of stopping boundaries, and there is a cost
to this adjustment. While the expectation is for the design to reduce the sample
size by stopping early, it is possible that for a given trial the group sequential design
will recruit more patients than a non-adaptive method would have (when no early
stopping criterion is met), usually by approximately 10% [184]. Due to uncertainty
about the length of the trial and number of patients before the trial commences,
each stage of the trial may or may not be the last, making logistics and planning
more complex than for a traditional fixed sample design.
2.4.2 Sample size re-assessment
Sample size re-assessment (also known as sample size re-estimation or sample size
re-calculation) seeks to ensure the use of an appropriate sample size for the trial
despite uncertainty about key parameters (such as the variance in the observations)
during the designing of the trial by re-assessing the required sample size during the
trial as shown in Figure 9. Typically, the re-estimation of the sample size focuses
on the estimation of design parameters at an interim analysis to re-calculate the
sample size in order to achieve, for example, a desired conditional power [185–187]
(the probability of rejecting the null hypothesis given the currently available data).
Usually, this is done with the option to increase but not the option to decrease
the sample size. In practice there is often a limit on what maximum sample size is
possible, as large increases to the sample size in this way can be inefficient [188]; in
practice if the estimated sample size exceeds the pre-set maximum then recruitment
is usually stopped (a form of stopping for futility).
Figure 9: Sample size re-assessment re-assessing key parameters using an interim
analysis to update the required sample size.
Sample size re-assessment may be either blinded or unblinded [189], while main-
taining the statistical integrity of the trial. In unblinded sample size re-estimation
interim analyses are conducted based on unblinded trial data; that is, the statisti-
cian performing the interim analysis will know which participants are in which trial
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arm. This is similar to group sequential designs although the aim here is not to stop
the trial early. Updated estimates of parameters related to the sample size are used
to re-assess the required sample size for the remainder of the trial [190–192]. Con-
versely, blinded sample size re-estimation only makes use of the combined blinded
trial data from all treatment arms when making decisions at the interim analyses
[185, 186, 193, 194]. Alterations to the sample size in this way have a minimal im-
pact on the type I error rate, even without formal adjustment [194]. The suitability
of blinded or unblinded re-assessment will depend on the parameters that require
re-estimation.
Example: Hade et al. [195] discuss a sample size re-assessment in a randomised
trial in breast cancer where the primary outcome is disease-free survival. Women
were randomised either to: immediate surgery in the next 1–6 days, which was ex-
pected to be in the follicular phase of the menstrual cycle; or to scheduled surgery
during the next mid-luteal phase of the menstrual cycle. Based on primary analysis
by log-rank test with a target of 80% power, with 5% two-sided type I error rate,
to detect a Hazard Ratio (HR) of 0.58 in favour of scheduled surgery, this required
113 events. With accrual time of 2 years and 4 additional years of follow up and
a 2−3% loss to follow up, the initial study design planned to randomise 340 women.
The HR used for the proposed sample size was felt to be optimistic based on more
current information and sources external to the trial. Based on a blinded sample
size re-assessment using the available data, the sample size was increased by 170
patients, to a total of 510 randomised patients (with a required 175 events) in order
to target a revised HR of 0.65.
Advantages: The main aim of sample size re-assessment is to ensure that the
trial recruits an appropriate number of patients, particularly when there is high
uncertainty about the design parameters before the trial begins whilst ensuring the
integrity of the trial is maintained. Sample size re-assessment designs are not as
complex as many other adaptive methods, which means the trial may be planned
and started more quickly. The fact that both unblinded and blinded methods are
available means that sample size re-assessment can be applied in many different
trial settings. There is an upward trend in the use of sample size re-assessment
in clinical practice, and as these designs become more widespread it will become
increasingly easy to put them forward.
Disadvantages: This is a method with relatively few drawbacks. There is a small
additional burden for statistical input at the interim analysis to properly estimate
the required sample size for the remainder of the trial, which requires appropriate
expertise in the case of both blinded and unblinded interim analyses. Most of the
practical issues that a sample size re-assessment design may bring (for example
time constraints or securing sufficing funding in advance) are similar to those faced
when using other adaptive designs.
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2.4.3 Summary
Methods to confirm a treatment works are the most widespread of the adaptive
designs we have considered [174], to the extent group sequential trials may even be
considered a standard approach. The group sequential framework forms a founda-
tion for many other adaptive methods due to its preservation of the integrity of the
trial results (for example, we discussed how MAMS designs may be constructed to
control the type I error rate, one method for this is to construct group sequential-
type tests).
3 Conclusions
Research into adaptive designs has become more prevalent across all stages of the
clinical development process, although this increase is not necessarily reflected by
their uptake in clinical practice. The suitability of an adaptive method depends
largely on the clinical question being addressed. We have presented four key clinical
questions for which corresponding adaptive designs may be of use across a wide
range of disease areas, study settings and endpoints. For each possible design, there
are advantages and disadvantages but in general there are some key themes: there
is an increase in efficiency of the design in terms of the expected number of patients
or a clear benefit in understanding the question of scientific interest; there are clear
ethical advantages to ensuring the right patients are given the best available treat-
ment whenever possible; and the key disadvantage is the additional burden, both
in the planning the trial and the interim analyses. Importantly, while the adaptive
methods can be highly effective when used in the correct scenario it is not always
the case an adaptive method is the best choice [196] and so careful consideration
must be taken as to if it is the correct choice.
Regulatory bodies are increasingly recognising the desire for the use of adaptive
designs and accepting their use although it is recommended regulators be engaged
early in the process whenever using any novel methodology [58, 197]. Funding bod-
ies are also increasingly comfortable with the use of adaptive designs, the TAILoR
trial discussed in Section 2.2.1 appears as a case study on the National Institute for
Health Research website [198]. Additionally new reporting guidance for adaptive
designs [199] have recently been published to facilitate uptake further.
We have not been exhaustive in our discussion of adaptive designs, focusing on
the key designs to answer the most common questions of clinical interest. Seamless
designs [102, 103, 200], which we have not discussed in detail, use similar adap-
tive design methodology to combine phases of clinical development: designs may
be inferentially seamless, where data from the earlier stage are incorporated into
the overall trial results; operationally seamless, avoiding any break in recruitment
between the stages of the development process but excluding data from earlier
stages from the final analysis of the latter; or both. There are many motivations for
conducting seamless designs [201], making it an active area of research [202].
For many years one major obstacle to the use of adaptive designs in practice has
been the lack of suitable software to aid both the design and conduct of trials. This
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issue is increasingly being tackled by those researching the methods, with many open
source packages available for the design and analysis of adaptive methods some of
which have been cited in this work. For example rpact [203] is an R package that
assists in the design and analysis of confirmatory clinical trials. In addition, there
is a steep learning curve to the implementation of such designs; training courses are
becoming increasingly available to address this.
From a methodology standpoint there are some further issues that go beyond
the level of detail we have discussed that should be considered when proposing an
adaptive design, for example potential information leakage or the introduction of
bias [204, 205]. The Practical Adaptive and Novel Designs and Analysis (PANDA)
toolkit [206] is under development at the time of writing and will be an online
resource that addresses and explains broader issues in the use of adaptive designs.
Despite the challenges in the design and analysis of an adaptive trial we believe
that under the right circumstance the benefits introduced by the increased flexibil-
ity clearly outweigh these issues.
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Method a.k.a Phase of
develop-
ment
Definition Benefits
Adaptive treat-
ment switching
II/III allow trial participants to switch
from allocated treatment to an al-
ternative
more trial participants receive pre-
ferred treatment
Bayesian adaptive I/II/III Bayesian methodology may be in-
corporated into many other designs
in the analysis and/or the interim
decision making
lower sample size due to utilisation
of prior information
Biomarker adap-
tive
Adaptive
signature
II/III identify and utilise biomarker infor-
mation to modify trial in progress to
target population
target the correct patient population
Covariate adjusted
response adaptive
CARA II/III shift allocation ratio towards
promising treatment(s) using
covariate information
more trial participants receive effec-
tive treatment
Continual re-
assessment
method
CRM I dose escalation design for find-
ing the maximum tolerated dose
(MTD)
more accurate and precise estima-
tion of the MTD than with 3+3 de-
signs, more patients treated at or
close to the MTD
Drop-the-loser DTL II/III drop inferior treatment arms (con-
trol group typically retained)
fewer trial participants assigned to
less effective treatments
Escalation with
overdose control
EWOC I dose escalation design to find MTD
using an allocation criterion to avoid
overdosing
more accurate and precise estima-
tion of the MTD than with 3+3 de-
signs, avoiding undesirable overdos-
ing of patients
Group sequential
design
II/III early stopping for futility or efficacy reduction in the expected sample
size, typically allowing for faster tri-
als requiring fewer patients (for a
small increase in the possible maxi-
mum sample size)
Multi-arm multi-
stage trial
MAMS II/III compare multiple treatments to a
common control, allow for early
stopping for efficacy or futility
common control requires fewer pa-
tients than conducting separate tri-
als, early stopping for efficacy or fu-
tility
MCP-Mod II combination of multiple compar-
isons and modeling approaches to
establish dose response model
efficient use of available data vs
pairwise comparisons
Population enrich-
ment
Adaptive
enrich-
ment
II/III allow for selection of target popula-
tion during the trial based on pre-
defined patient populations
target the correct patient population
Response adaptive
randomisation
Adaptive
alloca-
tion,
RAR
II/III shift allocation ratio towards more
promising treatment(s)
more trial participants receive effec-
tive treatment
Sample size re-
assessment
Sample
size re-
estimation/re-
calculation
II/III mid-course adjustment of the sam-
ple size, in either a blinded or un-
blinded fashion
raise the probability of a successful
trial
Seamless design Portfolio
decision
making
I/II/III merge trials from different phases
of development e.g. phase I/II or
phase II/III, can be inferentially
and/or operationally seamless
(inferential) more efficient use of
data from each phase of clinical de-
velopment / (operationl) faster clin-
ical development process and mov-
ing between stages
Table 1: Glossary of adaptive designs and descriptions of their typical applications
